Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds

Cancer Chemother Pharmacol. 1991;28(2):115-7. doi: 10.1007/BF00689699.

Abstract

5,10-Dideazatetrahydrofolic acid (DDATHF) is a potent inhibitor of glycinamide ribonucleotide transformylase, one of the folate-dependent key enzymes in de novo purine biosynthesis. The present report demonstrates that multiple membrane-transport routes may be involved in the cellular uptake of DDATHF. These routes include the classic reduced folate carrier and a membrane-associated folate-binding protein (mFBP). The role of an mFBP in the uptake of DDATHF was suggested from observations that (a) the mFBP showed a very high binding affinity for DDATHF, (b) murine and human leukemia cells expressing an mFBP were highly sensitive to growth inhibition by DDATHF, and (c) protection against this growth inhibition could be achieved using folic acid rather than reduced folate compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Biological Transport
  • Cell Division / drug effects
  • Cell Line
  • Cell Membrane / drug effects
  • Folic Acid Antagonists / metabolism
  • Folic Acid Antagonists / pharmacokinetics
  • Folic Acid Antagonists / therapeutic use*
  • Humans
  • Leukemia L1210 / drug therapy*
  • Leukemia L1210 / metabolism
  • Mice
  • Tetrahydrofolates / metabolism
  • Tetrahydrofolates / pharmacokinetics
  • Tetrahydrofolates / therapeutic use*

Substances

  • Antineoplastic Agents
  • Folic Acid Antagonists
  • Tetrahydrofolates
  • lometrexol